high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Coronary Syndrome
Conditions
Acute Coronary Syndrome, Carotid Atherosclerotic Plaque With Inflammation
Trial Timeline
Jun 29, 2017 → Jul 23, 2019
NCT ID
NCT04056169About high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe is a approved stage product being developed by Yuhan for Acute Coronary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04056169. Target conditions include Acute Coronary Syndrome, Carotid Atherosclerotic Plaque With Inflammation.
What happened to similar drugs?
20 of 20 similar drugs in Acute Coronary Syndrome were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04056169 | Approved | Completed |
Competing Products
20 competing products in Acute Coronary Syndrome